Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart, Inc. - Common Stock (NQ:VXRT)

0.3955 -0.0085 (-2.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vaxart, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Speculators Should Consider Buying Vaxart Stock
Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. 
Via InvestorPlace
Exposures COVID-19
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
VXRT stock needs to nail the next few studies of its Covid-19 vaccine candidate and prove its thesis to strengthen its bull case. 
Via InvestorPlace
Exposures COVID-19
Ocugen or Vaxart: Which Will Take Investors Further?
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
Exposures COVID-19
High Cash Burn Will Push Vaxart Stock Down To $1 Per Share
Failed clinical trials and high cash burn mean Vaxart is headed down to cash per share levels. That suggests VXRT stock is worth just $1. 
Via InvestorPlace
Exposures COVID-19
It Won’t Take Much for Vaxart Stock to Pop Once Again
Vaccine stocks are risky, but Americans nervous about a shot might make the difference for VXRT stock 
Via InvestorPlace
Exposures COVID-19
Is Vaxart a Buy?
Can this troubled coronavirus vaccine developer redeem itself and its investors? 
Via The Motley Fool
Exposures COVID-19
Vaxart’s No-Shot Vaccine Is a Potential Game Changer
VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data. 
Via InvestorPlace
Exposures COVID-19
Is Vaccine Maker Vaxart Worth Holding From Here?
As with most investment decisions, whether to hold depends on the situation. Here are some things to think about. 
Via The Motley Fool
Exposures COVID-19
Better Vaccine Stock: Ocugen or Vaxart?
Here's how the biotechs compare on several key fronts. 
Via The Motley Fool
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology... 
Via Benzinga
30 Stocks Moving in Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 94.2% to $2.33 in pre-market trading. Stealth BioTherapeutics showcased data for Elamipretide in dry age-related... 
Via Benzinga
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?
If it can reach the market of people that are hesitant to be vaccinated, yes. 
Via The Motley Fool
Exposures COVID-19
Vaxart Has 3 Advantages Over Pfizer and Moderna
Its coronavirus vaccine candidate may stand out, if upcoming trials are successful. 
Via The Motley Fool
Exposures COVID-19
70 Biggest Movers From Yesterday
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares surged 72.6% to close at $2.14 on Tuesday. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug... 
Via Benzinga
Exposures COVID-19
Why Vaxart Stock Is Surging Today
Investors are excited about the company's experimental COVID-19 vaccine. 
Via The Motley Fool
Exposures COVID-19
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares jumped 75.4% to $2.1750. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug candidates that target... 
Via Benzinga
Exposures COVID-19
Why Vaxart Shares Popped 78% in April
Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine. 
Via The Motley Fool
Exposures COVID-19
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
Vaxart Inc has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7... 
Via Benzinga
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained... 
Via Benzinga
Exposures COVID-19
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares rose 60.5% to $1.99 in pre-market trading. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug... 
Via Benzinga
Exposures COVID-19
52 Biggest Movers From Yesterday
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares climbed 102.5% to close at $14.62 on Monday after jumping 38% on Friday. Image Sensing Systems, Inc. (NASDAQ: ISNS)... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Precipio (NASDAQ: 
Via Benzinga
Vaxart Slides After Reporting Delay Of Trial For Potential COVID-19 Oral Vaccine
Shares of Vaxart are under pressure on Monday after the company reported worse-than-expected first quarter losses and said that its Phase II trial of VXA-CoV2-1 is now expected to start mid-year 2021... 
Via Talk Markets
Exposures COVID-19
Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.82% to 34,152.49 while the NASDAQ fell 0.36% to 13,912.07. The S&P also rose, gaining 0.41% to 4,198.29. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
2 Biopharma Stocks Looking To Make A Difference Against COVID-19: Technical Levels To Watch
Shares of Ocugen Inc. and Vaxart Inc. are moving Monday, May 3. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key variants of... 
Via Talk Markets
Vaxart Stock Plummets On Growing Losses As Investors Eye Covid Pill
Vaxart stock plummeted Monday ahead of a key presentation for its oral Covid vaccine and after the company reported growing first-quarter losses. 
Via Investor's Business Daily
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.